Chemoinformaics analysis of 1,2,3,4-Tetrahydroisoquinoline
| Molecular Weight | 133.194 | nRot | 0 |
| Heavy Atom Molecular Weight | 122.106 | nRig | 11 |
| Exact Molecular Weight | 133.089 | nRing | 2 |
| Solubility: LogS | -2.055 | nHRing | 1 |
| Solubility: LogP | 1.679 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 21 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 1 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 11 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 6 |
| nHA | 1 | APOL | 23.4647 |
| nHD | 1 | BPOL | 11.6053 |
| QED | 0.528 |
| Synth | 2.799 |
| Natural Product Likeliness | 0.529 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.032 |
| HIA | 0.005 |
| CACO-2 | -4.551 |
| MDCK | 0.0000276 |
| BBB | 0.699 |
| PPB | 0.660043 |
| VDSS | 2.372 |
| FU | 0.237201 |
| CYP1A2-inh | 0.984 |
| CYP1A2-sub | 0.88 |
| CYP2c19-inh | 0.246 |
| CYP2c19-sub | 0.75 |
| CYP2c9-inh | 0.026 |
| CYP2c9-sub | 0.826 |
| CYP2d6-inh | 0.608 |
| CYP2d6-sub | 0.919 |
| CYP3a4-inh | 0.061 |
| CYP3a4-sub | 0.422 |
| CL | 8.075 |
| T12 | 0.692 |
| hERG | 0.016 |
| Ames | 0.96 |
| ROA | 0.641 |
| SkinSen | 0.71 |
| Carcinogencity | 0.92 |
| EI | 0.976 |
| Respiratory | 0.543 |
| NR-Aromatase | 0.206 |
| Antiviral | No |
| Prediction | 0.893226 |